TLDR
HDL has direct anti-diabetic effects on pancreatic beta-cells, including promoting insulin synthesis and secretion, protecting against apoptosis, and maintaining beta-cell identity. These effects are mediated predominantly by apoA-I and apoA-II, acting through both lipid-dependent and lipid-independent mechanisms.
Mechanisms
- cAMP-PKA-FoxO1 pathway: ApoA-I binding activates G-protein-coupled receptors → adenylate cyclase → increased cAMP → PKA activation → FoxO1 nuclear export → derepression of insulin gene transcription.
- PDX1 upregulation: ApoA-I and apoA-II increase expression of pancreatic and duodenal homeobox 1 (PDX1), a transcription factor essential for beta-cell identity and survival.
- Apoptosis protection: HDL protects beta-cells from high glucose and free fatty acid-induced apoptosis via both ER stress-dependent and independent mechanisms.
- Cholesterol-independent: ApoA-I treatment of ABCA1/ABCG1-deficient beta-cells improves GSIS without altering islet cholesterol levels.
Clinical Evidence
- Single infusion of rHDL in 13 T2D patients reduced plasma glucose by increasing insulin secretion and skeletal muscle glucose uptake (Drew et al., landmark study).
- CETP inhibitor meta-analysis (n=75,102): 16% reduction in new-onset diabetes risk (RR 0.84, 95% CI 0.78–0.91).
- Obicetrapib pooled analysis (phase 3): reduced HbA1c in patients without diabetes; trend toward lower new-onset diabetes.
- Beta-cell function (HOMA-β) positively correlates with HDL anti-oxidative capacity and CEC in well-controlled T2D.